Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PepGen Ltd (PEPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: PEPG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.4% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.96M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 5 | Beta 1.29 | 52 Weeks Range 0.88 - 19.30 | Updated Date 07/9/2025 |
52 Weeks Range 0.88 - 19.30 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.84% | Return on Equity (TTM) -75.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -41550707 | Price to Sales(TTM) - |
Enterprise Value -41550707 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.11 | Shares Outstanding 32720900 | Shares Floating 12870456 |
Shares Outstanding 32720900 | Shares Floating 12870456 | ||
Percent Insiders 0.27 | Percent Institutions 95.95 |
Upturn AI SWOT
PepGen Ltd
Company Overview
History and Background
PepGen Ltd. is a biotechnology company focused on developing enhanced oligonucleotide therapies for neuromuscular and neurological diseases. Founded in 2018, the company has rapidly advanced its Enhanced Delivery Oligonucleotide (EDO) platform.
Core Business Areas
- Neuromuscular Diseases: Developing therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).
- Neurological Diseases: Exploring potential applications of EDO platform in other neurological disorders.
Leadership and Structure
The leadership team includes experienced pharmaceutical executives and scientists. The organizational structure involves research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- PGN-EDO51 (DMD): A therapy in clinical development for DMD patients amenable to exon 51 skipping. Currently in Phase 2 clinical trials. Competitors include Sarepta Therapeutics (SRPT) with their exon-skipping therapies, such as Exondys 51. Market share for exon-skipping therapies is fragmented, with SRPT holding a significant portion, but it is growing.
- PGN-EDODM1 (DM1): A therapy in clinical development for DM1. Currently in Phase 1 clinical trials. No direct competitors exist for this approach, but other companies are developing DM1 therapies such as antisense oligonucleotides. Market is currently untapped.
Market Dynamics
Industry Overview
The oligonucleotide therapeutics market is growing rapidly, driven by advances in drug delivery and RNA-targeting technologies. The market is segmented by disease type and therapeutic area.
Positioning
PepGen is positioned as an innovator in oligonucleotide delivery, with its EDO platform potentially offering improved efficacy and safety compared to existing therapies. Competitive advantages include enhanced tissue penetration and reduced off-target effects.
Total Addressable Market (TAM)
The TAM for neuromuscular and neurological diseases is estimated to be billions of dollars. PepGen is targeting specific patient populations within these larger markets. For DMD specifically, the market is expected to reach $4 billion by 2028. PepGen is aiming to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Proprietary EDO platform
- Strong preclinical data
- Experienced management team
- Focus on underserved patient populations
Weaknesses
- Early-stage clinical development
- High reliance on platform technology
- Limited commercial experience
- Dependence on funding for R&D
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Orphan drug designation for target indications
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- Biogen (BIIB)
Competitive Landscape
PepGen's EDO platform offers a potential advantage over existing therapies, but SRPT and BIIB have established market presence. PepGen needs to demonstrate superior clinical efficacy to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in preclinical and early clinical development.
Future Projections: Future growth depends on positive clinical trial results and potential regulatory approvals. Analyst estimates vary based on clinical data and market potential.
Recent Initiatives: Recent initiatives include advancing clinical trials for PGN-EDO51 and PGN-EDODM1 and exploring new applications of the EDO platform.
Summary
PepGen is an early-stage biotech with a promising drug delivery platform, focused on neuromuscular and neurological disorders. While its EDO technology has the potential to address unmet needs, the company faces competition from established players and relies on successful clinical trial outcomes. A strong cash position and strategic partnerships will be crucial for its success. The company's success depends heavily on the clinical trials of their therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Company Press Releases
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PepGen Ltd
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-05-06 | President, CEO, Treasurer, Secretary & Director Dr. James G. McArthur Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://pepgen.com |
Full time employees 79 | Website https://pepgen.com | ||
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.